David Shaw’s TG Therapeutics TGTX Stock Holding History

David Shaw’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.27M	Buy	77,700 +62,500	+411%	+$2.56M	﹤0.01%	2527
2026 Q1	$505K	Sell	15,200 -52,900	-78%	-$1.58M	﹤0.01%	3856
2025 Q4	$2.03M	Sell	68,100 -17,700	-21%	-$578K	﹤0.01%	3039
2025 Q3	$3.1M	Sell	85,800 -21,500	-20%	-$708K	﹤0.01%	2618
2025 Q2	$3.86M	Buy	107,300 +44,800	+72%	+$1.67M	﹤0.01%	2228
2025 Q1	$2.46M	Buy	62,500 +6,600	+12%	+$222K	﹤0.01%	2453
2024 Q4	$1.68M	Buy	+55,900	New	+$1.6M	﹤0.01%	2855
2024 Q3	–	Sell	-18,400	Closed	-$327K	–	4888
2024 Q2	$327K	Buy	+18,400	New	+$294K	﹤0.01%	3843
2024 Q1	–	Sell	-11,200	Closed	-$191K	–	4734
2023 Q4	$191K	Hold	11,200	–	–	﹤0.01%	3888
2023 Q3	$93.6K	Hold	11,200	–	–	﹤0.01%	3859
2023 Q2	$278K	Buy	+11,200	New	+$289K	﹤0.01%	3621
2020 Q3	–	Sell	-50,000	Closed	-$974K	–	4158
2020 Q2	$974K	Buy	+50,000	New	+$805K	﹤0.01%	2959
2018 Q2	–	Sell	-21,900	Closed	-$311K	–	3894
2018 Q1	$311K	Buy	+21,900	New	+$280K	﹤0.01%	3132

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

David Shaw's TGTX Position: Q2 2026 in Review

David Shaw increased its TG Therapeutics (TGTX) stake by 476% in Q2 2026, buying an estimated $115M and bringing the position to 3,400,808 shares worth $187M. The position accounts for 0.09% of the portfolio, ranked #237.

David Shaw first reported a position in TGTX in Q1 2015 and has held it in 40 quarters since. 426 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

David Shaw held 3,400,808 shares of TG Therapeutics worth $187M as of Q2 2026.
David Shaw bought 2,810,761 TG Therapeutics shares in Q2 2026, an estimated $115M.
TG Therapeutics made up 0.09% of David Shaw's portfolio in Q2 2026, its #237 holding.
David Shaw first reported a position in TG Therapeutics in Q1 2015 and has held it in 40 quarters since.
426 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.